Menu

Blog

Archive for the ‘neuropharmacology’ tag

Jul 30, 2019

Dr. Deborah Mash, Professor of Neurology and Molecular and Cellular Pharmacology, Director of the Brain Endowment Bank at the University of Miami, and CEO of DemeRx — Ira Pastor — ideaXme Show

Posted by in categories: aging, biotech/medical, business, chemistry, genetics, health, life extension, neuroscience, science, transhumanism

Jul 23, 2019

Dr. Calixto Machado, MD. PhD. Clinical Neurophysiology and Neurology; Author of “Brain Death: A Reappraisal” — ideaXme Show — Ira Pastor

Posted by in categories: aging, bioengineering, biotech/medical, cryonics, DNA, life extension, neuroscience, science, transhumanism

Apr 20, 2016

Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study

Posted by in categories: aging, bioengineering, biological, biotech/medical, cryonics, disruptive technology, futurism, health, life extension, neuroscience

Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of novel biologics for complex regeneration and disease reversion, and Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational therapeutic applications of autologous stem cells, have announced that they have received IRB approval for a study focusing on a novel combinatorial approach to clinical intervention in the state of brain death in humans.

This first trial, within the portfolio of Bioquark’s Reanima Project (http://www.reanima.tech) is entitled “Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury” (https://clinicaltrials.gov/ct2/show/NCT02742857?term=bioquark&rank=1), will enroll an initial 20 subjects, and be conducted at Anupam Hospital in Rudrapur, Uttarakhand India.

brainimage

Continue reading “Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study” »

Sep 15, 2015

The Imminence of Transhuman Technologies

Posted by in categories: bioengineering, ethics, existential risks, genetics, health, innovation, neuroscience

Progress always seems to ride a slippery slope. Innovations generally bring a plethora of potential benefits and just as many dangers, the obvious and the hidden. Technologies that tamper with our biological constructs is well underway in the neuro- and biotech industries. Historically, innovations in medicine have usually been beneficial on the aggregate.

But these new breakthroughs go beyond preventing and healing pre-existing causes. Transhuman technologies hold the promise of enhancing who we are as individuals and potentially as an entire species, and the decisions surrounding these technologies are far from simple. Dr. Nayef Al-Rodhan, a philosopher, neuroscientist, and director of the Geneva Center for Security Policy, believes we should be acting now to prepare for the inevitable and the unpredictable ramifications.

Framing Human Motivation

Considering our mixed track record as a species in rolling out groundbreaking innovations, discussing and finding potential solutions to many of the hidden dangers, and obvious ones, seems more than reasonable. One of the more puzzling questions is, where do we begin to have a pragmatic conversation on the ethics of these technologies?

There are plenty of theories about what drive human decisions, not least because human morality is infinitely complex and our minds crave frames through which to make sense of chaos. Dr. Al-Rodhan has his own conception of what drives human motivations. He makes meaning using the lens of “5 P’s” – Power, Pride, Profit, Pleasure, and Permanence – which he posits drive human motivations. “This is my view, the foundation of my outlook…this perceived emotion of self interest drives our moral compass.”

Continue reading “The Imminence of Transhuman Technologies” »